
BUZZ-Avidity Biosciences rises on report of Novartis buyout deal

Shares of drug developer Avidity Biosciencesrise 17.6% to $44.99 Swiss drugmaker Novartis (NOVN.S) has approached U.S. biotech Avidity with a potential takeover offer to boost its drug pipeline, the Financial Times reported “As a matter of policy, we do not comment on rumors or speculation” - Avidity Avidity has a market capitalisation of $4.61 billion, according to data compiled by LSEGIncluding session’s moves, stock up ~23% YTD
Shares of drug developer Avidity Biosciences (RNA.O) rise 17.6% to $44.99 Swiss drugmaker Novartis (NOVN.S) has approached U.S. biotech Avidity with a potential takeover offer to boost its drug pipeline, the Financial Times reported “As a matter of policy, we do not comment on rumors or speculation” - Avidity Avidity has a market capitalisation of $4.61 billion, according to data compiled by LSEG
Including session’s moves, stock up ~23% YTD
